Medical
Stay up-to-date on the latest medical cannabis research, news, and information with Business of Cannabis. Learn about new treatments, laws, and more.
Medical · page 4
- Patient Access
‘Everything in Our Power’: German Patient Groups Fight to Overturn Cannabis Insurance Cuts
Earlier this month (July 10, 2026), the German government voted through a sweeping set of provisions set to significantly impact medical cannabis patients who have their prescriptions covered by their statutory health insurance.
- Prescribers & Clinics
The Human Side of Hypergrowth: Recruitment, Culture and Maintaining Standards at Releaf
The UK has another new Prime Minister, Andy Burnham, who has wasted no time in laying out his plans to fundamentally reform the country’s creaking healthcare infrastructure.
- Clinical Research
A Cannabis Flavonoid Stopped Up to 99% of Cancer-Cell Growth in Lab Tests
Standard Seed Corporation (SSC), a cutting edge AI botanical-research company, believes it has identified a compound native to cannabis which could inhibit the growth of cancer cells by over 90% in some of the most aggressive forms of cancer.
- Medical Cannabis
Cannabis Use Among Teens Flat After German Partial Legalisation, But Medical Market Continues Rapid Expansion
Germany’s Cannabis Act (CanG) has not led to an increase in use among young people, according to new peer-reviewed research adding to the growing body of evidence contradicting the harms predicted by the reform’s critics.
- Clinical Research
Argent Trades Global Rights to Lead Cannabis Drug For Debt Relief in New $5.5m Deal
Argent BioPharma (RGT), formerly MGC Pharmaceuticals, has sold the global commercialisation rights of its leading epilepsy drug, CannEpil, in order to clear a sizable chunk of its debt.
- Opinion
Patients First: What Training the Police Taught Me About Medical Cannabis
As new national guidance instructs officers to treat medical cannabis users as patients first, James Duckenfield, CEO of Glass Pharms, reflects on what training police forces has taught him about the gap between the law and the general understanding of the legal landscape, and how the industry as a whole can help close it.
- Prescribers & Clinics
Cantourage Bets on Own Brand to Defend Flower Margins
Cantourage Group SE has announced the launch of its first proprietary medical cannabis brand for the German market, in a meaningful pivot for the distributor.
- Medical Cannabis
Measuring What Matters: Why Outcomes Will Decide the Future of Cannabis Medicine
The UK medical cannabis sector has spent seven years arguing for access.
- Pharmaceutical
Ananda Pharma Doses First Patient in NIHR-Backed CIPN Trial
Ananda Pharma has dosed the first patient in the ACTiON trial, a Phase 2 NIHR-funded study evaluating MRX1, the company’s proprietary CBD-based oral solution, as a treatment for chemotherapy-induced peripheral neuropathy (CIPN), a debilitating nerve-damage condition caused by chemotherapy for which no effective therapies currently exist.
- Cultivation
Rua Bioscience Signs its Largest-Ever Export Deal With Unnamed UK Cannabis Clinic
New Zealand-listed Rua Bioscience (NZX: RUA) has agreed a sales and distribution deal with one of the UK’s largest medicinal cannabis clinic and distribution businesses, expected to generate NZ$10m in revenue over two years, the company’s largest export contract to date.
- Medical Cannabis
Curaleaf Becomes First to Register Cannabis Preparations Under Spain’s New Medical Framework
Spain’s medicines regulator has officially approved the first two oil-based preparations as part of its recently approved national medical cannabis scheme.
- Pharmaceutical
World’s Largest CBD Insomnia Trial Could Hand Avecho an Australian Monopoly
The world’s largest clinical trial on cannabidiol (CBD) as a treatment for insomnia has been given the green light to complete its Phase III trial, transforming the fortunes of Avecho Biotechnology, and potentially the lives of insomnia sufferers worldwide.
